Researchers at the American Cancer Society found that perceptions of electronic or e-cigarettes as being “more harmful” than cigarettes by adults in the United States more than doubled between 2019-2020 and perceptions of e-cigarettes as “less harmful” declined between 2018-2020.
FDA granted Orphan Drug Designation to stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer.
The Parker Institute for Cancer Immunotherapy and National Resilience Inc. announced a five-year strategic alliance to develop next-generation cancer therapies.
Dana-Farber Cancer Institute, Gustave Roussy, and L’Institut Servier signed a cooperation agreement to foster collaboration among oncology researchers.
FDA announced the launch of the “Next Legends” Youth E-cigarette Prevention Campaign, which aims to protect youth from the dangers of tobacco use. The campaign will educate American Indian/Alaska Native youth, ages 12-17, about the harms of vaping through unique branding and tailored messaging.
Cancer organizations and pharmaceutical companies have formed a coalition that seeks to develop licensing agreements to improve access to essential cancer drugs in low- and lower-middle income countries (LLMICs).
Winship Cancer Institute of Emory University was awarded a P01 program project grant from NCI to support research aimed at improving the effectiveness of immunotherapy for lung cancer in patients with a mutation of the LKB1 gene, a group for whom present immunotherapy options do not provide robust benefit.
The Sylvester Comprehensive Cancer Center has begun constructing the Transformational Cancer Research Building, slated to open in 2024.
The Cancer Care Equity Act (SB 987) was unanimously passed by the California State Senate in a 34-0 vote. The bill is expected to be heard by the Assembly Health Committee next month.
Reena Philip was named associate director of biomarkers and precision oncology at FDA’s Oncology Center of Excellence.
